Betta Pharmaceuticals Co., Ltd.(SZ:300558) Zhong Guo Qing Nian Bao·2025-09-22 07:30Core Insights - The article highlights the entrepreneurial journey of Ding Lieming, chairman of Betta Pharmaceuticals, over the past 20 years, emphasizing the company's growth and its role in the biopharmaceutical industry in China [1] Company Overview - Betta Pharmaceuticals was established in 2006 in Linping District, Hangzhou, which significantly accelerated its clinical research and development processes [1] - The company has emerged as a leader in the biopharmaceutical sector, notably contributing to the development of China's first chemical targeted anti-cancer drug, Kaimena, breaking the technological monopoly of foreign pharmaceutical giants [1] Industry Development - Linping District has developed a biopharmaceutical industry cluster led by Betta Pharmaceuticals, including companies like Deshi Bio, Zhonghan Bio, Hu Qingyu Tang, and Baicheng Pharma [1] - By 2024, Linping District is projected to have 802 industrial enterprises above designated size, achieving an industrial output value of 1,760.02 billion yuan and an industrial added value of 447.53 billion yuan [1] - High-tech industries are expected to account for 84.04% of the district's industrial added value, indicating a strong focus on innovation and technology [1] Innovation and Support Systems - Linping District aims to build a comprehensive support system for major scientific and technological innovation platforms, inspired by the entrepreneurial innovation of Betta Pharmaceuticals [1] - The district is implementing digital reforms, reconstructing approval processes, and optimizing resource allocation to stimulate entrepreneurship and innovation among enterprises and talents [1]